A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients With DSM-IV-TR Schizophrenia Followed by Open-Label Treatment With LY2140023.
Phase of Trial: Phase III
Latest Information Update: 27 Sep 2013
At a glance
- Drugs Pomaglumetad methionil (Primary) ; Aripiprazole
- Indications Schizophrenia
- Focus Pharmacodynamics; Registrational
- 29 Aug 2012 Status changed from active, no longer recruiting to discontinued, according to an Eli Lilly media release.
- 15 May 2012 Planned end date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
- 15 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.